Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 21 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

7 trials in Phase 3/4

Results Transparency

0%

0 of 17 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
8(42.1%)
Phase 3
6(31.6%)
Phase 1
4(21.1%)
Phase 4
1(5.3%)
19Total
Phase 2(8)
Phase 3(6)
Phase 1(4)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (21)

Showing 20 of 21 trials
NCT07568522Active Not Recruiting

Long-Term Immunogenicity of Envacgen® in Children

Role: lead

NCT07178522Phase 3Active Not Recruiting

A Study to Evaluate the Immunogenicity and Safety of an EV71 Vaccine (Envacgen®) in Children Aged 6 to <10 Years Compared to Children Aged 2 to <6 Years

Role: lead

NCT05198596Phase 3Completed

A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 in Adults Aged 18 Years and Above

Role: lead

NCT05426343Phase 3Completed

A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Vaccine Compared With AZD1222

Role: lead

NCT05216601Phase 1Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901 or MVC-COV1901(Beta) Against COVID-19

Role: lead

NCT05197153Phase 2Completed

A Study to Evaluate the Safety and Immunogenicity of Booster With AZD1222, mRNA-1273, or MVC-COV1901 Against COVID-19

Role: lead

NCT05011526Phase 3Completed

A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 Against COVID-19 in Adults

Role: lead

NCT04072276Completed

Long-Term Immunogenicity Study of Inactivated EV71 Vaccine in Children

Role: lead

NCT05048849Phase 2Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of COVID-19 Vaccine, CT-COV-21 Extension Study

Role: lead

NCT05132855Phase 1Unknown

The Immune Response of Heterologous Boost Third Dose of mRNA and Protein COVID-19 Vaccine

Role: collaborator

NCT04822025Phase 2Completed

A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Elderly Adults

Role: lead

NCT05038618Phase 2Completed

A Study o Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901, CT-COV-21 Sub-study

Role: lead

NCT04951388Phase 2Completed

A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adolescents

Role: lead

NCT03865238Phase 3Completed

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of an EV71 Vaccine

Role: lead

NCT04487210Phase 1Completed

A Study to Evaluate the Safety and Immunogenicity of MVC-COV1901 Against COVID-19

Role: lead

NCT04695652Phase 2Completed

A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adult

Role: lead

NCT05097053Phase 4Unknown

A Heterologous 3rd COVID-19 Vaccine of MVC-COV1901 to Evaluate Immunogenicity and Safety in Adults With ChAdOx1-nCov-19

Role: collaborator

NCT03718468Phase 3Completed

A Study to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine

Role: lead

NCT03485144Phase 2Completed

A Clinical Study to Evaluate TV003 in Healthy Adults in Taiwan

Role: lead

NCT02200237Phase 2Completed

A Clinical Study for Inactivated Vaccine Against EV71

Role: lead